SCRA and SCRA Technology Ventures’ SC Launch program formally welcomed Israeli NeuroQuest to the Lowcountry at a networking event held at Roper St. Francis this past week. They happily presented NeuroQuest with a big check, making it the fourteenth company to enter the state through SCRA investment and the first landing party as a direct result of the SC–Israel Economic Development Mission.
Currently operating in Israel, NeuroQuest has established its US subsidiary and clinical development center in Charleston at the Roper St. Francis’ Clinical Biotechnology Research Institute. The company is developing blood-based immune biomarkers that produce early and accurate diagnostic and therapeutic tools for Alzheimer’s and ALS. The company is preparing for clinical studies of its diagnostic test, partnered with top national research centers.
“We are delighted to welcome NeuroQuest to South Carolina,” said SCRA CEO Bill Mahoney. “This is the first of many possible positive outcomes of the SC–Israeli mission. It is through collaborative efforts of all involved in this mission that this meaningful technology company comes to South Carolina, and we look forward to the contributions NeuroQuest will bring to our local economy and for those with Alzheimer’s and ALS.”
The SC–Israel Development Mission is co-sponsored by SCRA, the InterTech Group, the American-Israel Chamber of Commerce Southeast Region, Clemson University, the Medical University of South Carolina and the University of South Carolina.
“South Carolina has a wonderful business environment and we thank SCRA, SC Launch and Roper St. Francis for their support,” said NeuroQuest CEO Dan Touitou “We look forward to being a part of South Carolina’s Knowledge Economy and bringing quality diagnostic and therapeutic technologies to expanded markets.”
The SC Launch investment follows recent funding led by the North Charleston based InterTech Group, and the Maryland/Israel Trendlines Fund, managed by the Baltimore based Maryland/Israel Development Center. Seed financing for NeuroQuest was provided by the Trendlines Medical (formerly Misgav Venture Accelerator) and Israel’s Office of the Chief Scientist.